Back to results
US 12,005,078 B2Granted
Genetically engineered drug resistant T cells and methods of using the same
AssigneesThe UAB Research Foundation, Emory University, Children's Healthcare of Atlanta, Inc.
InventorsLawrence S. Lamb, H. Trent Spencer, G. Yancey Gillespie
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.
Claims30
A method of treating a subject suffering from a tumor, the method comprising:
- a. administering to the subject a cell composition comprising γδ T cells expressing at least NKG2D, a chimeric antigen receptor (CAR) directed to a tumor antigen,, and a polypeptide that confers resistance to a chemotherapeutic agent, wherein the chemotherapeutic agent increases the expression of a NKG2D ligand on the tumor;
- and
- b. administering to the subject the chemotherapeutic agent, wherein the chemotherapeutic agent is administered either before administration of the cell composition to the subject, after administration of the cell composition to the subject, concurrently with administration of the cell composition to the subject or any combination of the foregoing;
- wherein the CAR comprises an endodomain, and the endodomain consists of a CD3-zeta signaling domain or one costimulatory domain.
1 more element
Dependencies are inferred from the claim text.